Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Boehringer Ingelheim
Moodys
McKinsey

Last Updated: August 13, 2022

Investigational Drug Information for REL-1017


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug REL-1017?

REL-1017 is an investigational drug.

There have been 39 clinical trials for REL-1017. The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2012.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, B-Cell, and Depressive Disorder, Major. The leading clinical trial sponsors are Relmada Therapeutics, Inc., National Cancer Institute (NCI), and Merck Sharp & Dohme Corp.

Recent Clinical Trials for REL-1017
TitleSponsorPhase
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE InfectionsMerck Sharp & Dohme Corp.Phase 4
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE InfectionsAtrium HealthPhase 4
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)Relmada Therapeutics, Inc.Phase 3

See all REL-1017 clinical trials

Clinical Trial Summary for REL-1017

Top disease conditions for REL-1017
Top clinical trial sponsors for REL-1017

See all REL-1017 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Boehringer Ingelheim
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.